About 15% of ovarian cancer patients have a germline mutation in the BRCA1 or BRCA2 genes, and in these cases, chemotherapy can be supplemented with the administration of PARP inhibitors, which limit the regeneration of the cells as well as the further growth and proliferation of the tumor cells [7]. This evidence concerns the gene BRCA1 and ovarian cancer.